This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between psoriasis and alopecia areata, including immunologic and thereapeutic aspects, suggests that alefacept, which has been shown to be a safe and statistically significant beneficial therapeutic modality for the treatment of psorasis, may have thereapeutic value in alopecia areata.
Showing the most recent 10 out of 724 publications